Press

Novamind Partner to Acquire Specialized Ibogaine Group in Brazil

Apr 1 • 2 min read

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, is pleased to report that its strategic partner, Bienstar Wellness Corp., has signed a letter of intent to acquire BRC Saude Mental E Terapias Assistidas Ltda., a leader in specialized ibogaine treatments for substance use disorder…

Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain

Mar 31 • 4 min read

Cybin Inc. (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel feasibility study marks a truly exciting moment, not…

Albert Labs’ Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe Mycelia, as well as other Fungi Species

Mar 30 • 4 min read

Albert Labs International Corp. (CSE: ABRT), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines, based on mycelia of Psilocybe and other fungi, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a proprietary process. Albert Labs’ culturing process can significantly increase the…

Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Mar 29 • 4 min read

Cybin Inc. (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, is pleased to report the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (MDD). Data from in vivo preclinical studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the…

MindMed Reports Full Year 2021 Financial Results and Business Highlights

Mar 28 • 9 min read

Mind Medicine Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the full-year ended December 31, 2021. “2021 was a year of major advancements across all aspects of MindMed, with significant growth in our organization, development programs and research collaborations. We established a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441